The first approved mAb targeting EGFR as a single agent or in combination with irinotecan in patients with EGFR-expressing, metastatic and irinotecan-refractory colorectal carcinoma is the chimeric mAb cetuximab (Harding and Burtness, 2005), which has shown favourable efficacy (Cunningham et al, 2004). The gene discussed is EGFR; the disease is colorectal carcinoma.